EUVIMEDEUVIMED entdecken
Open Access

Outcomes of Patients With Treated Secondary Acute Myeloid Leukemia: A High‐Risk Subtype That Warrants an Independent Prognostic Designation

Jayastu Senapati iD, Hagop M Kantarjian iD, Fadi G Haddad iD, Nicholas J Short iD, Gautam Borthakur iD, Rashmi Kanagal-Shamanna iD, Guilin Tang iD, Elias Jabbour iD, Courtney D DiNardo iD, Naval Daver iD, Guillermo Montalban-Bravo iD, Vishrut Shah und 6 weitere

American Journal of Hematology · 2025

DOI: 10.1002/ajh.27561 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Hematology, 2025. Verfasst von Jayastu Senapati und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, University of Texas MD Anderson Cancer Center, Rama Guntupalli Endowment for Leukemia Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Patients who develop acute myeloid leukemia (AML) after having received treatment for myelodysplastic syndrome (MDS) or related conditions have particularly poor outcomes. This study analyzed adult patients with newly diagnosed AML who previously had MDS, chronic myelomonocytic leukemia (CMML), or MDS/myeloproliferative neoplasm (MPN) overlap syndrome, and who had received hypomethylating agents, chemotherapy, and/or allogeneic stem cell transplantation (HSCT) for these antecedent disorders. From January 2012 to August 2023, we included 673 patients with a median age of 70 years (range, 19–94); 536 (80%) had transformed from MDS, and the remainder from CMML or MDS‐MPN. Additionally, 149 patients (22%) had prior therapy for nonmyeloid malignancies. Among 497 evaluable patients, 289 (58%) had adverse‐risk (AR) cytogenetics, 34% had TP53 mutation/s, and 71% were classified as AR by the ELN 2017 criteria. Most patients (67%) received low‐intensity therapy (LIT) for AML, and 27% were treated with venetoclax. The overall response rate was 37%, and venetoclax improved the odds of response (OR = 2.5, 95% CI 1.6–3.7) in LIT–treated patients. At a median follow‐up of 43 months, the median relapse‐free survival (RFS) and overall survival (OS) were 4.6 and 4.8 months, respectively. Multivariate analysis showed that prior therapy for nonmyeloid disorders (HR = 1.30), ≥ 2 lines of therapy for antecedent myeloid disorders (HR = 1.23), and ELN AR risk (HR = 1.47) increased the hazards of death, while HSCT (HR = 0.50) was beneficial and validated on gradient‐boosted regression. TS‐AML is associated with poor outcomes irrespective of AML genomics and treatment, highlighting the need for its inclusion as an independent AR category for accurate prognostication and clinical trial reporting.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteHumansAgedMiddle AgedMaleFemaleAdultAged, 80 and overPrognosisMyelodysplastic SyndromesHematopoietic Stem Cell TransplantationYoung AdultNeoplasms, Second PrimaryBridged Bicyclo Compounds, HeterocyclicSulfonamidesTreatment OutcomeMyeloproliferative DisordersLeukemia, Myelomonocytic, Chronic

Stichwörter der Autor:innen

TP53myelodysplastic syndromesecondary acute myeloid leukemiastem cell transplantationvenetoclax

Substanzen

venetoclaxBridged Bicyclo Compounds, HeterocyclicSulfonamides

Autor:innen und Institutionen

  • Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

ORCID-Profile: Jayastu Senapati, Hagop M Kantarjian, Fadi G Haddad, Nicholas J Short, Gautam Borthakur, Rashmi Kanagal-Shamanna, Guilin Tang, Elias Jabbour, Courtney D DiNardo, Naval Daver, Guillermo Montalban-Bravo, Uday Popat, Guillermo Garcia-Manero, Farhad Ravandi, Tapan M Kadia

Förderung

  • NCI NIH HHS
  • University of Texas MD Anderson Cancer Center
  • Rama Guntupalli Endowment for Leukemia Research
  • University of Texas MD Anderson SPORE

Zitieren

APA

Senapati, J., Kantarjian, H. M., Haddad, F. G., Short, N. J., Borthakur, G., Kanagal-Shamanna, R., Tang, G., Jabbour, E., DiNardo, C. D., Daver, N., Montalban-Bravo, G., Shah, V., Alousi, A., Shpall, E., Popat, U., Garcia-Manero, G., Ravandi, F., & Kadia, T. M. (2025). Outcomes of Patients With Treated Secondary Acute Myeloid Leukemia: A High‐Risk Subtype That Warrants an Independent Prognostic Designation. American Journal of Hematology. https://doi.org/10.1002/ajh.27561

Vancouver

Senapati J, Kantarjian HM, Haddad FG, Short NJ, Borthakur G, Kanagal-Shamanna R, et al. Outcomes of Patients With Treated Secondary Acute Myeloid Leukemia: A High‐Risk Subtype That Warrants an Independent Prognostic Designation. American Journal of Hematology. 2025. doi:10.1002/ajh.27561

BibTeX
@article{Senapati2025,
  author = {Senapati, Jayastu and Kantarjian, Hagop M and Haddad, Fadi G and Short, Nicholas J and Borthakur, Gautam and Kanagal-Shamanna, Rashmi and Tang, Guilin and Jabbour, Elias and DiNardo, Courtney D and Daver, Naval and Montalban-Bravo, Guillermo and Shah, Vishrut and Alousi, Amin and Shpall, Elizabeth and Popat, Uday and Garcia-Manero, Guillermo and Ravandi, Farhad and Kadia, Tapan M},
  title = {Outcomes of Patients With Treated Secondary Acute Myeloid Leukemia: A High‐Risk Subtype That Warrants an Independent Prognostic Designation},
  journal = {American Journal of Hematology},
  year = {2025},
  doi = {10.1002/ajh.27561}
}
Kostenlos starten →